Exact Therapeutics appoints Dr Hilary Mcelwaine-Johnn as Chief Medical Officer
LONDON: Exact Therapeutics AS announced the appointment of Dr Hilary McElwaine-Johnn as Chief Medical Officer.
Dr McElwaine-Johnn will be based at the newly opened London office of EXACT-Tx at the Translation & Innovation Hub (i-Hub) at White City.
“We are delighted to welcome Hilary to EXACT Therapeutics AS where her unique experience in both therapeutics and drug delivery complemented by deep medical expertise will be pivotal in driving forward the development of ACT, both in the ongoing Phase I ACTIVATE study and beyond”, said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.
“Hilary joins EXACT-Tx at an exciting time as we expand our presence in the UK with the opening of our London office at the White City i-Hub in close proximity to the growing Imperial College campus”.
Dr McElwaine-Johnn gained her medical degree from Imperial College, London and is a Member of the Royal College of Physicians and Faculty of Pharmaceutical Medicine. Following clinical roles in general internal medicine and oncology, she has pursued a highly successful career in the pharmaceutical industry.
She has held a variety of senior medical positions including Vice President, Clinical, PowderMed Ltd (which was subsequently acquired by Pfizer), Chief Medical Officer of Vantia Ltd, PsiOxus Therapeutics Ltd and most recently Karus Therapeutics.
During this time Hilary has gained extensive experience in drug development in both oncology and other therapeutic indications as well as delivery technologies complemented by a range of successful interactions with Regulatory Authorities, partner companies and fundraising activities.
Dr McElwaine-Johnn commented: “I am excited to be joining EXACT Therapeutics in London to be part of a dynamic and innovative organization exploring the potential of the ACT platform to transform clinical practice across indications, particularly in the management of patients with cancer.
With a strong preclinical evidence base and clinical development of ACT already underway, I am looking forward to working with the clinical community in further investigating this exciting approach to ultrasound mediated therapeutic targeting.”
About The Author
